News / Taiwan / economic_daily
長聖 Reports 15% Revenue Growth, Advances CAR-T Clinical Trials
Health Technology · Biotechnology · economic_daily · 2026-11-04
6712
Cell therapy firm 長聖 posted an 8.92 billion NTD revenue for the first ten months, up 15.2%, while advancing its CAR-T drug clinical pipeline.
What Happened
Operational Data: 長聖 reported October revenue of NT$112 million, bringing the ten-month total to NT$892 million, a 15.23% increase year-over-year, with a Q1-Q3 EPS of NT$3.42.
R&D Progress: The company's proprietary allogeneic CAR-T drug, CAR001, is currently in Phase IIa clinical trials, showing promising preliminary efficacy in treating various solid tumors, including glioblastoma and colorectal cancer.
Business Strategy: The company maintains a dual-track strategy of operational growth and R&D, focusing on expanding its cell therapy and CDMO services while actively seeking international partnerships and licensing opportunities.
Future Outlook: With steady growth in core business segments and continued progress in clinical trials, analysts expect the company to maintain its growth momentum into next year as it expands its international regulatory footprint.